ArticleMicrosystems & nanoengineering2025
A wearable self-aid microneedle chip based on actively transdermal delivery of epinephrine.
Article in Microsystems & nanoengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Skin Barrier-Informed Topical and Transdermal Drug Delivery: Excipient-Driven Strategies, Vehicle Transformation, and Translational Challenges.Pharmaceutics · 2026Review
- Review
- Integrating Polymeric 3D-Printed Microneedles with Wearable Devices: Toward Smart and Personalized Healthcare Solutions.Polymers · 2025Review
- Dissolved bubble microneedle patches for co-delivery of hydrophobic and hydrophilic drugs to improve acne vulgaris therapy.Microsystems & nanoengineering · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Epinephrine is important for first aid and usually applied via injection, which is painful and problematic in operation, thereby making it difficult to self-delivery. In this study, a method to actively transdermal delivery of epinephrine is proposed based on incorporating microneedles with iontophoresis, and then a wearable device is fabricated for rapid and controllable self-delivery of epinephrine. The device consists of a hydrogel microneedle array, a conductive drug delivery hydrogel, iontophoresis electrodes, and an encapsulated cartridge with a spring and self-locking micro-mechanism. The microneedles create subcutaneous microchannels, allowing the epinephrine contained in the hydrogel to enter the body under the control of iontophoretic currents. The dosage and rate can be adjusted at different levels by pressing the button so that it can be used by different groups of people for rapid self-aid and recovery from fatigue. The device can be worn in advance if required. In-vitro tests showed that the transdermal delivery rate of the device was between 0.02642 and 0.1059 mg/h cm². As a proof-of-concept application, in-vivo experiments showed that the device could reverse life-threatening shock reactions in a piglet model of hemorrhagic shock through the delivery of epinephrine.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.